Literature DB >> 28003225

Muscle-specific microRNA-206 targets multiple components in dystrophic skeletal muscle representing beneficial adaptations.

Adel Amirouche1,2, Vanessa E Jahnke1, John A Lunde2, Nathalie Koulmann3, Damien G Freyssenet1, Bernard J Jasmin4.   

Abstract

Over the last several years, converging lines of evidence have indicated that miR-206 plays a pivotal role in promoting muscle differentiation and regeneration, thereby potentially impacting positively on the progression of neuromuscular disorders, including Duchenne muscular dystrophy (DMD). Despite several studies showing the regulatory function of miR-206 on target mRNAs in skeletal muscle cells, the effects of overexpression of miR-206 in dystrophic muscles remain to be established. Here, we found that miR-206 overexpression in mdx mouse muscles simultaneously targets multiple mRNAs and proteins implicated in satellite cell differentiation, muscle regeneration, and at the neuromuscular junction. Overexpression of miR-206 also increased the levels of several muscle-specific mRNAs/proteins, while enhancing utrophin A expression at the sarcolemma. Finally, we also observed that the increased expression of miR-206 in dystrophin-deficient mouse muscle decreased the production of proinflammatory cytokines and infiltration of macrophages. Taken together, our results show that miR-206 acts as a pleiotropic regulator that targets multiple key mRNAs and proteins expected to provide beneficial adaptations in dystrophic muscle, thus highlighting its therapeutic potential for DMD.
Copyright © 2017 the American Physiological Society.

Entities:  

Keywords:  Duchenne muscular dystrophy; Pax7; miR-206; neuromuscular disease; neuromuscular junction; regeneration; therapy; utrophin

Mesh:

Substances:

Year:  2016        PMID: 28003225     DOI: 10.1152/ajpcell.00185.2016

Source DB:  PubMed          Journal:  Am J Physiol Cell Physiol        ISSN: 0363-6143            Impact factor:   4.249


  6 in total

1.  The oncomir face of microRNA-206: A permanent miR-206 transfection study.

Authors:  Dóra Mihály; Gergő Papp; Zsolt Mervai; Andrea Reszegi; Péter Tátrai; Gábor Szalóki; Johanna Sápi; Zoltán Sápi
Journal:  Exp Biol Med (Maywood)       Date:  2018-08-15

2.  Circulating brain-enriched microRNAs as novel biomarkers for detection and differentiation of neurodegenerative diseases.

Authors:  Kira S Sheinerman; Jon B Toledo; Vladimir G Tsivinsky; David Irwin; Murray Grossman; Daniel Weintraub; Howard I Hurtig; Alice Chen-Plotkin; David A Wolk; Leo F McCluskey; Lauren B Elman; John Q Trojanowski; Samuil R Umansky
Journal:  Alzheimers Res Ther       Date:  2017-11-09       Impact factor: 6.982

3.  miR-146a deficiency does not aggravate muscular dystrophy in mdx mice.

Authors:  Iwona Bronisz-Budzyńska; Katarzyna Chwalenia; Olga Mucha; Paulina Podkalicka; Alicja Józkowicz; Agnieszka Łoboda; Magdalena Kozakowska; Józef Dulak
Journal:  Skelet Muscle       Date:  2019-08-14       Impact factor: 4.912

4.  Role of miRNAs and lncRNAs in dexamethasone-induced myotube atrophy in vitro.

Authors:  Yang Li; Huacai Shi; Rui Chen; Shanyao Zhou; Si Lei; Yanling She
Journal:  Exp Ther Med       Date:  2020-12-16       Impact factor: 2.447

5.  Release of MicroRNAs into Body Fluids from Ten Organs of Mice Exposed to Cigarette Smoke.

Authors:  Alberto Izzotti; Mariagrazia Longobardi; Sebastiano La Maestra; Rosanna T Micale; Alessandra Pulliero; Anna Camoirano; Marta Geretto; Francesco D'Agostini; Roumen Balansky; Mark Steven Miller; Vernon E Steele; Silvio De Flora
Journal:  Theranostics       Date:  2018-03-08       Impact factor: 11.556

6.  Embryonic myosin is a regeneration marker to monitor utrophin-based therapies for DMD.

Authors:  Simon Guiraud; Benjamin Edwards; Sarah E Squire; Lee Moir; Adam Berg; Arran Babbs; Nesrine Ramadan; Matthew J Wood; Kay E Davies
Journal:  Hum Mol Genet       Date:  2019-01-15       Impact factor: 6.150

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.